文献速递胸部肿瘤乳腺癌消化系统肿瘤

长期应答者进展后重启同种抗PD-(L)1治疗的结局

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
PubMed 文献 · Eur J Cancer · 2018-07-30

该研究回顾性分析了13例在I期试验中按方案中断抗PD-(L)1治疗的肿瘤控制患者,中断后中位无治疗间期12.6个月,8例进展后重启同种免疫治疗,重启后最佳应答为2例部分缓解和6例疾病稳定,中位PFS2为12.9个月,未发生3/4级不良事件。

要点

  • 按方案中断抗PD-(L)1后,进展时重启同种治疗可行。
  • 重启后25%患者获部分缓解,75%获疾病稳定。
  • 重启后中位PFS2为12.9个月,未观察到3/4级事件。

核心结论

  • 数据提示抗PD-(L)1治疗按计划中断后若出现进展,应重启同种抗PD-(L)1治疗。

研究设计与样本

  • 回顾性报告13例在I期试验中按方案中断抗PD-(L)1治疗的肿瘤控制患者,进展后可重启同种免疫治疗。

主要发现

  • 患者瘤种包括结直肠微卫星高度不稳定(n=5)、尿路上皮癌(n=3)、黑色素瘤(n=2)、非小细胞肺癌(n=2)和三阴性乳腺癌(n=1),中位治疗时间12个月(范围10.6-12)。
  • 最佳应答为完全缓解1例(8%)、部分缓解10例(77%)和疾病稳定2例(15%)。
  • 中位PFS1为24.4个月(范围15.8-49),中断后中位无治疗间期12.6个月(范围4-39.7)。
  • 8例进展后重启治疗,最佳应答为部分缓解2例(25%)和疾病稳定6例(75%),中位PFS2为12.9个月(范围5-35.4)。
  • 研究期间未发生3/4级事件。

临床怎么用

  • 对于按计划中断抗PD-(L)1治疗后进展的患者,可考虑重启同种抗PD-(L)1治疗。

局限性

  • 样本量小(13例),为回顾性报告,需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term responders have been observed with anti-programmed death 1 and anti-programmed death ligand 1 (anti-PD(L)1). Optimal duration of therapy in responding and stable disease (SD) patients is unclear with various attitudes encompassing treatment until progression disease, stopping therapy after a defined timeframe. PATIENTS AND METHODS: We report the experience of 13 patients who discontinued immune checkpoint inhibitor in phase I trials as per protocol while experiencing a tumour-controlled disease. According to protocols, patients could restart the same immunotherapy if radiological or clinical progression occurred. RESULTS: Patients were treated for colorectal microsatellite instability-high genotype (n = 5), urothelial carcinoma (n = 3), melanoma (n = 2), non-small-cell lung cancer (n = 2) and triple-negative breast cancer (n = 1) for a median time of 12 months (range 10.6-12). Patients achieved 1 (8%) complete response, 10 (77%) partial response (PR) and 2 (15%) SD. The median progression-free survival 1 (PFS1) defined as the time from the first infusion until progression was 24.4 months (range 15.8-49). The median time free-treatment after discontinuation was 12.6 months (range 4-39.7). Eight patients experienced disease progression and were retreated. Best responses observed after rechallenging were 2 PR (25%) and 6 SD (75%). Median PFS2 defined from the first day of retreatment until disease progression or the last news was 12.9 months (range 5-35.4). No grade 3/4 events occurred during the study period. CONCLUSION: Our data suggest that anti-PD(L)1 therapy should be resumed if progression occurs after a planned anti-PD(L)1 interruption. Further prospective studies are needed to confirm these results.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bernard-Tessier A, Baldini C, Martin P, et al. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018. PMID: 30071444. doi:10.1016/j.ejca.2018.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。